Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa

First subject dosed in Phase I study to evaluate safety and tolerability of…


Infex Awarded Biomedical Catalyst Grant For COV-X Project

Alderley Park, Cheshire, U.K - Infex Therapeutics, a leading anti-infectives…


CARB-X Receives Additional $370m from U.S. Government and Wellcome

Enables continued investment in innovative projects to tackle the growing…


Infex welcomes NICE and NHS England’s new antibiotic reimbursement mechanism

Alderley Park, Cheshire - Infex Therapeutics, one of the UK’s leading…


Infex scientists achieve breakthrough to overcome critical priority drug resistant infections

Alderley Park, Cheshire – One of the UK’s leading infectious disease biotech…


Infex agrees partnership with Colibri Scientific to provide services for RESP-X program

Alderley Park, Cheshire Infex Therapeutics has today announced a deal with…


Infex scientists achieve breakthrough with potential new drug for Omicron and new coronavirus strains

Alderley Park, Cheshire –  One of the UK’s leading infectious disease biotech…


Budget’s R&D investment increase must propel action on AMR, says Dr Peter Jackson of Infex Therapeutics

Commenting in reaction to the Chancellor’s budget on 27th October 2021, Dr…


Infex Therapeutics sharpens Covid focus with new CRUK Newcastle partnership

Alderley Park, Cheshire - Infex Therapeutics is pressing ahead with a major…